SOLICITATION NOTICE
A -- ADJUVANT DEVELOPMENT PROGRAM
- Notice Date
- 9/18/2007
- Notice Type
- Solicitation Notice
- NAICS
- 541710
— Research and Development in the Physical, Engineering, and Life Sciences
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Office of Acquisitions 6700 B Rockledge Room 3214 MSC7612, Bethesda, MD, 20892-7612, UNITED STATES
- ZIP Code
- 20892-7612
- Solicitation Number
- BAA-NIH-NIAID-DAIT-08-11
- Response Due
- 1/4/2008
- Archive Date
- 2/4/2008
- Point of Contact
- Doris McClain, Contract Specialist, Phone 301-451-3692, Fax 301-402-0972, - Wanda Neal, Contract Officer, Phone 301-451-3685, Fax 301-480-4675,
- E-Mail Address
-
mcclainj@niaid.nih.gov, WNeal@niaid.nih.gov
- Description
- The NIAID, NIH, and other DHHS agencies, support extramural research to develop new products to protect the public from the health consequences of biological agents that might be used in acts of bioterrorism and from emerging/re-emerging diseases, such as West Nile Virus, multi-drug resistant Tuberculosis, and Dengue Fever. The biological agents deemed to pose the greatest threat to civilian populations are prioritized in the NIAID Category A, B and C Priority Pathogens and toxins list, which is available at: http://www3.niaid.nih.gov/Biodefense/bandc_priority.htm. The NIAID contributes to meeting the goals for host defense described in the NIAID Strategic Plan for Biodefense (http://www3.niaid.nih.gov/Biodefense/Research/strat_plan.htm) by supporting the development of new candidate vaccine adjuvants that stimulate the innate immune response to: protect against pathogenic infection; specifically activate the appropriate arms of the immune response; and result in stronger, more protective vaccines against NIAID Category A, B, and C Priority Pathogens. This novel class of adjuvants stimulates the innate immune response and demonstrates strong adjuvant properties in animal models. These candidate vaccine adjuvants will be developed for human use with currently licensed or new investigational vaccines, to protect against NIAID Category A, B, or C Priority Pathogens. This initiative supports the development of candidate vaccine adjuvants through immunological characterization studies, lead compound optimization, and/or Investigational New Drug (IND)-enabling studies. Work must include studies on at least one Category A, B, or C Priority Pathogen. Additional studies may be focused on other human infectious pathogens with sufficient justification of an ultimate application to Biodefense. Studies with HIV will not be supported. Candidate vaccine adjuvants eligible for support must meet the following requirements: (1) the adjuvant has been previously identified and characterized as safe and functioning via innate immune responses; (2) there is documented evidence that demonstrates a mechanism of action for the adjuvant; (3) the proposed Product Development Plan will significantly advance the development of the candidate adjuvant within the five-year period of contract performance; and (4) where possible, the adjuvant has been shown to safely augment the ability of a vaccine to protect against a NIAID Category A, B, or C Priority Pathogen upon pathogen challenge in an in vivo animal model. Proposals will be evaluated based on the following technical evaluation criteria: (1) Proposed Product Development Plan, (2) Scientific and Technical Personnel, (3) Project Management, and (4) Facilities, Equipment and Other Resources. It is anticipated that 3-5 cost reimbursement; completion type contracts will be awarded for a 5-year period of performance beginning on or about September 18, 2008. It is estimated that the provision of FTEs will be approximately as follows: 6.2 FTEs Any responsible offeror may submit a proposal which will be considered by the Agency. This BAA will be available electronically on/about October 4, 2007, and may be accessed through FedBizOpps http://www.fedbizopps.gov/. This notice does not commit the Government to award a contract. No collect calls will be accepted. No facsimile transmissions will be accepted. See Government-Wide Numbered Note 26. NOTE: THIS NOTICE WAS NOT POSTED TO FEDBIZOPPS ON THE DATE INDICATED IN THE NOTICE ITSELF (18-SEP-2007); HOWEVER, IT DID APPEAR IN THE FEDBIZOPPS FTP FEED ON THIS DATE. PLEASE CONTACT fbo.support@gsa.gov REGARDING THIS ISSUE.
- Web Link
-
Link to FedBizOpps document.
(http://www.fbo.gov/spg/HHS/NIH/NIAID/BAA-NIH-NIAID-DAIT-08-11/listing.html)
- Place of Performance
- Address: 6700-B Rockledge Drive, Room 3214 Bethesda, Maryland
- Zip Code: 20892
- Country: UNITED STATES
- Zip Code: 20892
- Record
- SN01410310-F 20070920/070919144133 (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |